Pfizer Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2013 • Pharmaceuticals: 87.2% • Others: 12.8%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Company has a healthy return on capital (ROCE) of 24.0%
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 0.92x)
- Company has been maintaining a healthy dividend payout of 47.5%
- Company comfortably covers its interest (103.0x coverage)
- Company has a consistent dividend-paying track record
CONS
- Recent results are weak - TTM profit is down 12.7% versus prior year
- Company has delivered a poor sales growth of 2.4% over past five years
- Recurring exceptional / one-off items are inflating headline profit
- Company has delivered a poor profit growth of 7.7% over past five years
- Stock is trading at 5.1x its book value
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| PFIZER | 4062.05 | 135.52 | 18582.96 | 1.85 | 204.47 | 6.63 | 653.17 | 8.31 | 23.39 | 37.90 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 531 | 575 | 540 | 547 | 563 | 589 | 538 | 592 | 603 | 642 | 645 | 629 | 653 | |
| 421 | 393 | 387 | 357 | 385 | 399 | 392 | 364 | 393 | 412 | 417 | 393 | 421 | |
| Operating Profit | 111 | 183 | 153 | 189 | 177 | 189 | 146 | 227 | 210 | 230 | 228 | 236 | 232 |
| OPM % | 20.84% | 31.75% | 28.25% | 34.65% | 31.53% | 32.15% | 27.14% | 38.43% | 34.83% | 35.80% | 35.38% | 37.50% | 35.49% |
| 33 | 36 | 44 | 75 | 42 | 43 | 43 | 217 | 67 | 42 | -20 | 50 | 45 | |
| Interest | 3 | 3 | 3 | 7 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 2 | 1 |
| Depreciation | 16 | 15 | 18 | 14 | 15 | 15 | 15 | 16 | 14 | 14 | 14 | 15 | 14 |
| Profit before Tax | 126 | 201 | 176 | 244 | 203 | 215 | 172 | 426 | 260 | 255 | 192 | 269 | 277 |
| Tax % | 25.62% | 25.71% | 26.12% | 26.65% | 25.62% | 26.43% | 26.00% | 22.28% | 26.12% | 25.98% | 26.11% | 25.67% | 26.10% |
| Net Profit | 94 | 149 | 130 | 179 | 151 | 158 | 128 | 331 | 192 | 189 | 142 | 200 | 204 |
| 20.44 | 32.56 | 28.42 | 39.09 | 32.94 | 34.61 | 27.89 | 72.34 | 41.91 | 41.32 | 31.01 | 43.68 | 44.69 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,966 | 1,969 | 2,082 | 2,152 | 2,239 | 2,611 | 2,425 | 2,193 | 2,281 | 2,520 | 2,570 | |
| 1,616 | 1,468 | 1,516 | 1,579 | 1,526 | 1,775 | 1,616 | 1,558 | 1,541 | 1,615 | 1,644 | |
| Operating Profit | 350 | 501 | 566 | 573 | 712 | 836 | 809 | 635 | 740 | 904 | 926 |
| OPM % | 17.81% | 25.43% | 27.17% | 26.62% | 31.82% | 32.02% | 33.36% | 28.97% | 32.45% | 35.89% | 36.03% |
| 232 | 114 | 167 | 184 | 81 | 63 | 134 | 188 | 345 | 139 | 116 | |
| Interest | 2 | 1 | 2 | 11 | 15 | 11 | 13 | 15 | 8 | 10 | 8 |
| Depreciation | 63 | 66 | 71 | 103 | 109 | 115 | 106 | 62 | 61 | 58 | 58 |
| Profit before Tax | 517 | 548 | 660 | 642 | 669 | 773 | 824 | 746 | 1,016 | 976 | 993 |
| Tax % | 34.84% | 34.28% | 34.98% | 20.76% | 25.59% | 20.74% | 24.28% | 26.10% | 24.46% | 25.96% | 25.95% |
| Net Profit | 337 | 360 | 429 | 509 | 498 | 613 | 624 | 551 | 768 | 722 | 735 |
| EPS | 73.61 | 78.70 | 93.78 | 111.28 | 108.77 | 133.89 | 136.38 | 120.51 | 167.78 | 157.91 | — |
| Dividend Payout % | 27.17% | 25.41% | 23.99% | 296.54% | 32.18% | 26.14% | 51.33% | 29.04% | 98.34% | 47.50% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 2%
- 5 Years:
- 2%
- 3 Years:
- 1%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 9%
- 5 Years:
- 8%
- 3 Years:
- 5%
STOCK PRICE CAGR
- 10 Years:
- 7%
- 5 Years:
- -8%
- 3 Years:
- 2%
- 1 Year:
- -21%
RETURN ON EQUITY
- 10 Years:
- 17%
- 5 Years:
- 19%
- 3 Years:
- 18%
- Last Year:
- 17%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 |
| 2,373 | 2,637 | 2,966 | 3,350 | 2,347 | 2,819 | 3,162 | 3,550 | 4,172 | 4,157 | |
| 2 | 2 | 2 | 91 | 51 | 130 | 96 | 57 | 70 | 46 | |
| Trade Payables | 388 | 496 | 436 | 427 | 284 | 264 | 217 | 166 | 152 | 216 |
| 452 | 509 | 490 | 491 | 525 | 595 | 383 | 356 | 403 | 385 | |
| Total Liabilities | 3,261 | 3,690 | 3,940 | 4,405 | 3,252 | 3,854 | 3,903 | 4,175 | 4,842 | 4,850 |
| 867 | 917 | 854 | 942 | 865 | 841 | 749 | 713 | 724 | 678 | |
| Capital Work in Progress | 4 | 1 | 0 | 1 | 3 | 1 | 8 | 0 | 8 | 20 |
| 322 | 297 | 387 | 431 | 435 | 449 | 418 | 434 | 476 | 473 | |
| 0 | 0 | 0 | 0 | 0 | 143 | 0 | 188 | 193 | 182 | |
| Cash & Bank | 1,523 | 1,772 | 1,914 | 2,220 | 1,115 | 1,643 | 1,860 | 2,047 | 2,801 | 3,111 |
| 545 | 703 | 785 | 812 | 835 | 777 | 869 | 794 | 641 | 386 | |
| Total Assets | 3,261 | 3,690 | 3,940 | 4,405 | 3,252 | 3,854 | 3,903 | 4,175 | 4,842 | 4,850 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 512 | 525 | 335 | 536 | 631 | 667 | 658 | 257 | 660 | 968 | |
| Cash from Investing | -250 | -238 | 35 | 1,530 | -469 | -575 | -36 | 54 | -71 | -562 |
| Cash from Financing | -83 | -110 | -110 | -164 | -1,571 | -181 | -346 | -235 | -205 | -798 |
| -3 | -17 | 23 | 1,690 | -1,613 | -88 | -26 | 75 | 383 | -392 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-07 - Please find enclosed outcome of the Board Meeting held today i.e., September 7, 2026.
2026-08-04 - Pfizer Limited has informed the Exchange about Copy of Newspaper Publication
2026-07-29 - Pfizer Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 28, 2026. Further, the company has informed the Exchange regarding voting results.
2026-07-28 - Pfizer Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 28, 2026
2026-07-28 - Pfizer Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-27 - Pfizer Limited has informed the Exchange regarding Change in Director(s) of the company.
2026-07-17 - The Exchange has sought clarification from Pfizer Limited with respect to recent news item captioned Pfizer suspends Premarin vaginal cream in India, raising concerns over menopause care.. The response from the Company is attached.
2026-07-17 - The Exchange has sought clarification from Pfizer Limited with respect to recent news item captioned Pfizer suspends Premarin vaginal cream in India, raising concerns over menopause care.. The response from the Company is awaited.
2026-07-10 - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.
News
Recent coverage and analyst commentary for PFIZER
Loading news…
AI Stock Analyst
Pfizer Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account